Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 10 X users, with an upper bound of 28,337 followers.

Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis https://t.co/EntN927iBZ https://t.co/CMO6xTRkjF

14 Apr 2023

Reply Repost Favourite

RT @FrontOncology: New research: Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune che…

11 Apr 2023

Reply Repost Favourite

RT @FrontOncology: New research: Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune che…

10 Apr 2023

Reply Repost Favourite

RT @FrontOncology: New research: Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune che…

10 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.